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Intervention on Patients with Diabetic Foot UlcerationThe UK National Institute for Health and Care Excellence
(NICE) published its report on inpatient management of
diabetic foot problems in 2011.1 This should be very sig-
niﬁcant for the vascular clinician; after all, we are all aware
of the increasing worldwide pandemic of diabetic disease
and its inﬂuence on our day-to-day vascular practice.2 NICE
posed a deceptively simple review question “When is the
optimal time for surgical management (including revascu-
larisation and orthopaedic interventions) to prevent
amputation for diabetic foot problems?” The response was
equally simple: “The systematic search retrieved 9817
studies. No studies were identiﬁed that met the inclusion
criteria; therefore no evidence statement was generated”.
Is it really true that this question cannot be answered by
any research in the whole ﬁeld of vascular surgery and
intervention? And this being such a major sector of our
clinical work?
We believe that NICE is correct, and that the research
effort is being wrongly led by inadequate reporting stan-
dards. Virtually all vascular procedures are reported in
terms of patency, primary and secondary (assisted), and
limb salvage. We contend that these reporting standards
are historical, developed at a time when smoking-related
atherosclerotic disease was more prevalent, and less use-
ful in an age where diabetic neuroischaemic ulceration is
becoming the most important cause for vascular
intervention.
Most vascular interventions are for occlusive disease.
Therefore patency, or prevention of re-occlusion, whether
primary, or after a second intervention, seems to be a
reasonable procedural target for reporting. After all, durable
patency after intervention is always preferable to re-
occlusion. However, when the focus changes from the
procedure to clinical outcome, this standard can be seen as
prone to both Type 1 and Type 2 error. If we consider
wound healing in a diabetic foot, it is not uncommon for
wounds to heal in the absence of durable patency (or any
procedure at all, despite documented vascular disease) and
for wounds to fail to heal despite durable patency.3,4
Limb salvage is another cornerstone of the reporting
standards for vascular intervention. Although preservation
of the limb, and avoidance of amputation, is certainly a
long-term goal of therapy, this objective becomes less1078-5884/$ e see front matter  2015 European Society for Vascular
Surgery. Published by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejvs.2015.02.017meaningful when reported over short time period,
conventionally over 1 year. This convention is an extension
of the concept of critical ischaemia; that the natural history
of the vascular disease without intervention will cause the
limb to succumb to pain and tissue loss enough to require
amputation within a short time. It is applicable to limbs that
exhibit rest pain, non-healing ulceration, and gangrene,
with objective evidence of ischaemia. Whether or not such
a limb would progress to amputation is an educated guess
before the intervention, and a self-fulﬁlling prophecy after
an intervention. There is less guesswork if there is pro-
gressive tissue loss such as gangrene before intervention.
However, most presentations of diabetes for foot clinic
evaluation are diabetic neuroischaemic ulcer. These ulcers
generally have a background of vascular disease, deﬁned in
different ways, usually with a pulse or ankle brachial pres-
sure index deﬁcit. The median time to healing of ulceration
is 3 (2e7) months in patients with neuropathy and absent
foot pulses, and up to 50% of these ulcers will heal without
vascular intervention.4,5 Perhaps progression to amputation
is not as inevitable as assumed in the concept of critical
ischaemia and limb salvage. A 1-year limb salvage rate in
these chronic ulcers may not be very meaningful experi-
ence. For example, Hinchliffe et al.6 found in a systematic
review of revascularisation of diabetic foot that a limb
salvage rate of 80e85% was reported, despite ulcer healing
of only 60%, similar to healing rates without intervention.
Let us consider a common vascular/diabetic challenge.
The patient with chronic, often recurrent diabetic neuro-
ischaemic foot ulceration presents with intact popliteal
pulse and imaging-conﬁrmed diffuse tibial occlusive dis-
ease. Depending on local expertise and practice, this patient
may be treated conservatively, recommended for tibial
angioplasty or stent, or for poplitealetibial/pedal bypass.
We are unsure which of these strategies is likely to promote
healing, reduce recurrence rates, or avoid major amputa-
tion. Not only is there no randomised controlled trial, but
even looking at the procedural data, there is little to go on.
For example, reports on poplitealetibial surgical bypass
quote patency rates of 73% and limb salvage of 87% at 1
year7; reports of tibial angioplasty quote primary patency of
46% and limb salvage of 84% at 1 year,8 but there are no
data on wound healing in any of these reports. Given that
the impressive limb salvage rates are not meaningful in this
chronic recurrent context, there is little guidance from the
available literature to advance the management of this
(rather common) patient.
140 EditorialThis article is an appeal to update the reporting standards
for diabetic foot disease. Although diabetic patients can
suffer the normal vascular presentations of claudication,
rest pain and digital gangrene, the more common condition
of neuroischaemic ulcer deserves to be considered, and
reported distinctly from mainstream vascular disease. This is
because it ﬁts poorly with the concept of critical ischaemia
because of its chronicity and the relapsing remitting nature
of neuroischaemic ulcer disease. These patients are not on a
pathway to limb loss by infarction or amputation; or, if they
are, that pathway is moving very slowly.
We propose that diabetic neuroischaemic ulcer be treated
differently to the standard concept of critical limb ischaemia.
Although ischaemia undoubtedly retards healing, many of
these will heal without vascular improvement3 and pro-
gression to limb threatening status is slow. Reporting stan-
dards for intervention in diabetic neuroischaemic ulceration
should be adjusted accordingly, to emphasise clinical out-
comes such as ulcer healing, reduction in ulcer extent, pain
relief, and quality of life.9 Patency rates should still be re-
ported to match technical with clinical results.
We consider that the use of limb salvage be abandoned
completely in diabetic neuroischaemia as it represents an
optimistic and complacent view of an area of practice that
requires improvement and development. We particularly
appeal for new reporting standards to precede and stimu-
late high-quality randomised controlled trials of revascu-
larisation in this area. These standards need to be relevant
to wound healing over a meaningful period of time. Ul-
ceration affecting the feet of patients with diabetes is a
relapsing, remitting condition, with over 50% ulcers recur-
ring over a 1e3-year period. Therefore long-term follow-up
and prevention of recurrence over time should also be a
reporting standard.10,11 The prevention of major amputa-
tion remains an overarching goal, but needs to be ratiﬁed
over a longer time period, and probably on a population
rather than an individual scale.
New outcome reporting standards for diabetic neuro-
ischaemia are necessary, but unlikely to be sufﬁcient for
new research. Many other factors apart from background
ischaemia can affect healing. Diabetic foot wounds will
need to be classiﬁed for ulcer characteristics, extent of
infection, background neuropathy, and patient factors for a
meaningful comparison between different treatments: a
recent system (WiFI) has been described and is incorpo-
rated in the forthcoming BASIL-2 trial.12
We repeat NICE’s recommended questions for research:
Does early revascularisation improve outcomes in patients
with diabetes and a foot ulcer? What are the best indicators
of the need to revascularise the leg in patients with dia-
betes and a neuroischaemic foot ulcer?
The vascular community has previously demonstrated its
ability to come together and support randomised controlled
trials in important areas of practice. We feel that it is time
to address the place of vascular interventions in the bur-
geoning disease of epidemic scale, which represents one of
the greatest threats to health in the new century. Thedeﬁnition of new outcome measures and classiﬁcations is
an important enabling step to this endeavour.
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